Vimarsana
Biggest News Aggregation in the World

Page 38 - Viewray Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Viewray Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Viewray Inc Today - Breaking & Trending Today

ViewRay to Host a Virtual Clinical Data Event for Investors and Analysts on March 16, 2022 - Vimarsana News

ViewRay to Host a Virtual Clinical Data Event for Investors and Analysts on March 16, 2022

/PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company will host a Virtual Clinical Data Event for Investors and Analysts on Wednesday,...

ViewRay makes a board change, enters into cooperation agreement with large shareholder - Vimarsana News

ViewRay makes a board change, enters into cooperation agreement with large shareholder

The Oakwood Village-based maker of the MRIdian MRI-guided radiation therapy system has a new board member to replace one who resigned, and it says it's working with a consultant representing New York City-based Hudson Executive Capital to come up with ways to 'enhance shareholder returns.'

ViewRay Enters into Cooperation Agreement with Hudson Executive Capital - Vimarsana News

ViewRay Enters into Cooperation Agreement with Hudson Executive Capital

/PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that it has reached an agreement with Hudson Executive Capital LP ("HEC") to appoint Susan...

ViewRay to Host a Virtual Clinical Data Event for Investors and Analysts on March 16, 2022 - Vimarsana News

ViewRay to Host a Virtual Clinical Data Event for Investors and Analysts on March 16, 2022

/PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company will host a Virtual Clinical Data Event for Investors and Analysts on Wednesday,...

First Toxicity Results from SCIMITAR Prospective Phase II Trial Signal Favorable Toxicity Profile of Post-Prostatectomy Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer - Vimarsana News

First Toxicity Results from SCIMITAR Prospective Phase II Trial Signal Favorable Toxicity Profile of Post-Prostatectomy Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer

/PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced the first toxicity results from the prospective single-arm Phase II SCIMITAR trial. A secondary...